Phase I Study of Veliparib (ABT-888) Combined with Cisplatin and Vinorelbine in Advanced Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer

PURPOSE: Cisplatin is synergistic with vinorelbine and the poly(ADP-ribose) polymerase (PARP) inhibitor veliparib, and has anti-neoplastic activity in TNBC and BRCA mutation-associated breast cancer. This phase I study assessed veliparib with cisplatin and vinorelbine. PATIENTS AND METHODS: A 3+3 do...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: Rodler, Eve T., Kurland, Brenda F., Griffin, Melissa, Gralow, Julie R., Porter, Peggy, Yeh, Rosa F., Gadi, Vijayakrishna K., Guenthoer, Jamie, Beumer, Jan H., Korde, Larissa, Strychor, Sandra, Kiesel, Brian F., Linden, Hannah M., Thompson, John A., Swisher, Elizabeth, Chai, Xiaoyu, Shepherd, Stacie, Giranda, Vincent, Specht, Jennifer M.
Formato: Artigo
Idioma:Inglês
Publicado em: 2016
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4911292/
https://ncbi.nlm.nih.gov/pubmed/26801247
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-15-2137
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados